{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T01:25:48Z","timestamp":1790040348320,"version":"4.0.1"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T00:00:00Z","timestamp":1660003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Allogeneic hematopoietic cell transplant (allo-HCT) for eligible patients with acute myeloid leukemia (AML) in first complete remission is a central treatment paradigm to achieve durable remission. However, disease relapse after allo-HCT remains a significant concern and generally portends a poor prognosis. There is significant interest regarding the role for maintenance therapy after allo-HCT for patients with high risk of relapse, regardless of the presence of measurable residual disease. While there are currently no therapies approved for maintenance therapy for AML after allo-HCT, there are a number of ongoing investigations examining the role of maintenance therapies that include targeted agents against FLT3-ITD or IDH mutations, hypomethylating agents, immunomodulatory therapies and cellular therapies. In this review, we examine the current landscape and future strategies for maintenance therapy for AML after allo-HCT.<\/jats:p>","DOI":"10.3389\/fonc.2022.895771","type":"journal-article","created":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T14:43:08Z","timestamp":1660056188000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Maintenance therapy for AML after allogeneic HCT"],"prefix":"10.3389","volume":"12","author":[{"given":"Rahul K.","family":"Nayak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Bin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,9]]},"reference":[{"key":"B1","unstructured":"Hematopoietic cell transplantation in the treatment of newly diagnosed adult acute myeloid leukemia: An evidence-based review from the American society of transplantation and cellular therapy - transplantation and cellular therapy"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.243410","article-title":"Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the acute leukemia working party of the European society for blood and marrow transplantation","volume":"105","author":"Bazarbachi","year":"2020","journal-title":"Haematologica"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.167","article-title":"Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. a review from the ALWP of the EBMT","volume":"51","author":"Tsirigotis","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.9868","article-title":"Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: A retrospective analysis","volume":"30","author":"Brunet","year":"2012","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.09.007","article-title":"Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia","volume":"20","author":"Chen","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"B6","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/bjh.14260","article-title":"Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission","volume":"175","author":"Brunner","year":"2016","journal-title":"Br J Haematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3\u2013internal tandem duplication mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30455-1","article-title":"Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial","volume":"21","author":"Xuan","year":"2020","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1182\/blood-2018-99-113582","article-title":"Radius: A phase 2 randomized trial investigating standard of care \u00b1 midostaurin after allogeneic stem cell transplant in FLT3-ITD-Mutated AML","volume":"132","author":"Maziarz","year":"2018","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4484","article-title":"Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells","volume":"24","author":"Mathew","year":"2018","journal-title":"Nat Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"4602","DOI":"10.1182\/blood-2019-124322","article-title":"BMT CTN protocol 1506: A phase 3 trial of gilteritinib as maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with FLT3-ITD+ AML","volume":"134","author":"Levis","year":"2019","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24959","article-title":"Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant","volume":"93","author":"Sandmaier","year":"2018","journal-title":"Am J Hematol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"TPS7073","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS7073","article-title":"Phase 3 (P3) study of quizartinib (Q) or placebo (P) with induction (IND) and consolidation chemotherapy (CON) and as maintenance (MN) in patients (pts) with newly diagnosed (NDx) FLT3-ITD\u2013positive acute myeloid leukemia (AML): the QuANTUM-first study","volume":"34","author":"Erba","year":"2016","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.02.028","article-title":"Outcomes for patients with IDH-mutated acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation","volume":"27","author":"Chen","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1182\/blood-2020-140176","article-title":"A phase I study of the IDH2 inhibitor enasidenib as maintenance therapy for IDH2-mutant myeloid neoplasms following hematopoietic cell transplantation","volume":"136","author":"Fathi","year":"2020","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.09.022","article-title":"Nonmyeloablative allogeneic transplantation with post-transplant cyclophosphamide for acute myeloid leukemia with IDH mutations: A single center experience","volume":"22","author":"Ambinder","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B17","unstructured":"Mechanisms of action of hypomethylating agents: Endogenous retroelements at the epicenter\n            KordellaC\n            LamprianidouE\n            KotsianidisI\n          2021"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01218-0","article-title":"Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies","volume":"35","author":"Stomper","year":"2021","journal-title":"Leukemia"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004444","article-title":"Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission","volume":"383","author":"Wei","year":"2020","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"997.e1","DOI":"10.1016\/j.jtct.2021.09.005","article-title":"Hypomethylating agents and FLT3 inhibitors as maintenance treatment for acute myeloid leukemia and myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation\u2013a systematic review and meta-analysis","volume":"27","author":"Bewersdorf","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.06.007","article-title":"A phase II multicenter study of the addition of azacitidine to reduced-intensity conditioning allogeneic transplant for high-risk myelodysplasia (and older patients with acute myeloid leukemia): Results of CALGB 100801 (Alliance)","volume":"25","author":"Vij","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002544","article-title":"A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients","volume":"4","author":"Oran","year":"2020","journal-title":"Blood Adv"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03277","article-title":"Effect of rhG-CSF combined with decitabine prophylaxis on relapse of patients with high-risk MRD-negative AML after HSCT: An open-label, multicenter, randomized controlled trial","volume":"38","author":"Gao","year":"2020","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2021000278","article-title":"Oral hypomethylating agents: beyond convenience in MDS","volume":"2021","author":"Griffiths","year":"2021","journal-title":"Hematology"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.06.016","article-title":"CC-486 maintenance after stem cell transplantation in patients with acute myeloid leukemia or myelodysplastic syndromes","volume":"24","author":"de Lima","year":"2018","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001991","article-title":"Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse","volume":"4","author":"Kent","year":"2020","journal-title":"Blood Adv"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-138832","article-title":"Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse","volume":"136","author":"Kent","year":"2020","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-01207-4","article-title":"Outcomes following hematopoietic stem cell transplantation in patients treated with standard chemotherapy with or without gemtuzumab ozogamicin for acute myeloid leukemia","volume":"56","author":"Pautas","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B29","unstructured":"Post-transplant maintenance therapy with azacitidine and gemtuzumab ozogamicin for high-risk acute myeloid leukaemia"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.242","article-title":"Phase I\/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)","volume":"31","author":"Bug","year":"2017","journal-title":"Leukemia"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.04.014","article-title":"Lenalidomide maintenance for high risk multiple myeloma after allogeneic hematopoietic cell transplantation","volume":"20","author":"Alsina","year":"2014","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.067629","article-title":"Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial","volume":"97","author":"Sockel","year":"2012","journal-title":"Haematologica"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01444-1","article-title":"Safety and tolerability of lenalidomide maintenance in post-transplant acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"56","author":"Pham","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00889","article-title":"Combination lenalidomide and azacitidine: A novel salvage therapy in patients who relapse after allogeneic stem-cell transplantation for acute myeloid leukemia","volume":"37","author":"Craddock","year":"2019","journal-title":"J Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601202","article-title":"Ipilimumab for patients with relapse after allogeneic transplantation","volume":"375","author":"Davids","year":"2016","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-761346","article-title":"PD-1 blockade for relapsed lymphoma post\u2013allogeneic hematopoietic cell transplant: high response rate but frequent GVHD","volume":"130","author":"Haverkos","year":"2017","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705898","article-title":"Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation","volume":"41","author":"Loren","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"B38","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.bbmt.2012.07.021","article-title":"High alloreactivity of low-dose prophylactic donor lymphocyte infusion in patients with acute leukemia undergoing allogeneic hematopoietic cell transplantation with an alemtuzumab-containing conditioning regimen","volume":"19","author":"Liga","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.234","article-title":"Long-term results of adjuvant donor lymphocyte transfusion in AML after allogeneic stem cell transplantation","volume":"51","author":"Jedlickova","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01515-3","article-title":"Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia","volume":"57","author":"Schmid","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0536-y","article-title":"Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome","volume":"54","author":"Guillaume","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"B42","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.blre.2018.12.001","article-title":"Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era","volume":"34","author":"Liu","year":"2019","journal-title":"Blood Rev"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0530192100","article-title":"Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia","volume":"100","author":"Marijt","year":"2003","journal-title":"Proc Natl Acad Sci"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.06.001","article-title":"Multicenter analyses demonstrate significant clinical effects of minor histocompatibility antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic stem cell transplantation","volume":"19","author":"Spierings","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"B45","unstructured":"MacbeathG\n          ASHDiscovery of TSC-101: A first-in-Class natural HA-2-Specific TCR to treat leukemia following hematopoietic stem cell transplant therapy2021"},{"key":"B46","unstructured":"Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.01.019","article-title":"Natural killer cells in allogeneic transplantation: Effect on engraftment, graft- versus-tumor, and graft-versus-Host responses","volume":"15","author":"Gill","year":"2009","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200503","article-title":"HLA-C\u2013dependent prevention of leukemia relapse by donor activating KIR2DS1","volume":"367","author":"Venstrom","year":"2012","journal-title":"N Engl J Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01349-4","article-title":"Decrease post-transplant relapse using donor-derived expanded NK-cells","volume":"36","author":"Ciurea","year":"2022","journal-title":"Leukemia"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112673","article-title":"Phase I trial of prophylactic donor-derived IL-2-Activated NK cell infusion after allogeneic hematopoietic stem cell transplantation from a matched sibling donor","volume":"13","author":"Devillier","year":"2021","journal-title":"Cancers"},{"key":"B51","doi-asserted-by":"crossref","unstructured":"ShapiroR\n          ASHCytokine-induced memory-like NK cells exhibit massive expansion and long-term persistence after infusion post-haploidentical stem cell transplantation: A report of the first three cases in a phase I trial2020","DOI":"10.1182\/blood-2020-133933"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-11-785873","article-title":"Vaccine therapy in hematologic malignancies","volume":"131","author":"Avigan","year":"2018","journal-title":"Blood"},{"key":"B53","unstructured":"Maintenance of complete remission after allogeneic stem cell transplantation in leukemia patients treated with wilms tumor 1 peptide vaccine"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006255","article-title":"GM-CSF secreting leukemia cell vaccination for MDS\/AML after allogeneic HSCT: a randomized double blinded phase 2 trial","volume":"6","author":"Ho","year":"2021","journal-title":"Blood Adv"},{"key":"B55","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1182\/blood-2021-154166","article-title":"Post-transplant vaccination with a personalized dendritic Cell\/AML fusion cell vaccine for prevention of relapse","volume":"138","author":"Liegel","year":"2021","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.3826","article-title":"Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: Time to move toward a minimal residual disease\u2013based definition of complete remission","volume":"34","author":"Araki","year":"2016","journal-title":"J Clin Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.159343","article-title":"Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis","volume":"102","author":"Buckley","year":"2017","journal-title":"Haematologica"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.6395","article-title":"When the minimal becomes measurable","volume":"34","author":"Hourigan","year":"2016","journal-title":"J Clin Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03011","article-title":"Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease","volume":"38","author":"Hourigan","year":"2020","journal-title":"J Clin Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014520","article-title":"Impact of diagnostic genetics on remission MRD and transplantation outcomes in older AML patients","volume":"139","author":"Murdock","year":"2022","journal-title":"Blood"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.895771\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T14:43:14Z","timestamp":1660056194000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.895771\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,9]]},"references-count":60,"alternative-id":["10.3389\/fonc.2022.895771"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.895771","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,9]]},"article-number":"895771"}}